Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Chardan Capital

Solid Biosciences (NASDAQ:SLDB)‘s stock had its “buy” rating reiterated by equities researchers at Chardan Capital in a note issued to investors on Friday,Benzinga reports. They currently have a $15.00 price objective on the stock. Chardan Capital’s target price indicates a potential upside of 113.37% from the company’s previous close.

Several other equities analysts also recently issued reports on SLDB. Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. Citigroup reiterated a “market outperform” rating on shares of Solid Biosciences in a research report on Wednesday, December 17th. Wedbush reissued an “outperform” rating and issued a $14.00 target price on shares of Solid Biosciences in a report on Wednesday, March 11th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of Solid Biosciences in a research report on Friday. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Solid Biosciences Stock Down 1.3%

SLDB opened at $7.03 on Friday. The company has a market cap of $547.71 million, a PE ratio of -3.48 and a beta of 2.65. Solid Biosciences has a twelve month low of $2.41 and a twelve month high of $8.72. The company has a 50-day moving average price of $6.43 and a 200 day moving average price of $5.80.

Solid Biosciences (NASDAQ:SLDB) last issued its earnings results on Thursday, March 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.01. As a group, sell-side analysts expect that Solid Biosciences will post -2.84 earnings per share for the current year.

Insider Activity at Solid Biosciences

In other news, CFO Kevin Tan sold 26,837 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $6.44, for a total transaction of $172,830.28. Following the completion of the sale, the chief financial officer owned 108,984 shares in the company, valued at approximately $701,856.96. This represents a 19.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Alexander Cumbo sold 80,258 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $516,861.52. Following the transaction, the chief executive officer directly owned 270,931 shares in the company, valued at approximately $1,744,795.64. This represents a 22.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 597,672 shares of company stock worth $3,816,546 in the last three months. Company insiders own 1.90% of the company’s stock.

Institutional Trading of Solid Biosciences

A number of hedge funds have recently added to or reduced their stakes in SLDB. MetLife Investment Management LLC grew its stake in shares of Solid Biosciences by 10.4% in the 4th quarter. MetLife Investment Management LLC now owns 33,202 shares of the company’s stock valued at $187,000 after purchasing an additional 3,124 shares during the last quarter. Quantum Private Wealth LLC raised its stake in shares of Solid Biosciences by 3.9% during the third quarter. Quantum Private Wealth LLC now owns 94,231 shares of the company’s stock worth $581,000 after purchasing an additional 3,500 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Solid Biosciences by 208.6% during the second quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after purchasing an additional 4,063 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Solid Biosciences by 205.5% during the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock worth $33,000 after purchasing an additional 4,534 shares during the period. Finally, Intech Investment Management LLC increased its stake in Solid Biosciences by 15.2% in the 4th quarter. Intech Investment Management LLC now owns 34,485 shares of the company’s stock valued at $194,000 after buying an additional 4,539 shares during the period. 81.46% of the stock is owned by institutional investors and hedge funds.

More Solid Biosciences News

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Guggenheim started coverage with a Buy and a $26 price target (implies ~272% upside from recent levels), giving formal street-level momentum and a large upside case for the stock. Guggenheim starts coverage (Benzinga)
• Positive Sentiment: Needham reaffirmed Buy with a $19 price target, signaling continued analyst conviction in the company’s clinical progress and longer-term value. Needham reaffirms buy (Benzinga)
• Positive Sentiment: Chardan reaffirmed its Buy rating and $15 target, adding to the cluster of upgrade/reaffirmation headlines that can attract investor attention and trading demand. Chardan reaffirms buy (TickerReport)
• Positive Sentiment: Solid reported positive interim Phase 1/2 INSPIRE data for SGT-003 at the 2026 MDA meeting; the readout highlights generally favorable tolerability in 41 dosed participants—this is the primary fundamental catalyst supporting higher valuations. SGT-003 interim data (GlobeNewswire)
• Neutral Sentiment: The company issued its Q4 and full-year 2025 results and broader business updates; the release contains operational context and program timelines that investors will parse for runway and development plans. Q4 & full-year 2025 results (FinanzNachrichten)
• Negative Sentiment: SLDB missed Q4 EPS expectations (reported -$0.53 vs. consensus -$0.48), underlining ongoing losses and near-term profitability risk that likely capped the stock’s upside today. Earnings press release (Quartr)

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.